| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2162295 | Seminars in Oncology | 2011 | 6 Pages |
Abstract
Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, platinum salts (eg, cisplatin, carboplatin), pegylated liposomal doxorubicin, etoposide, and irinotecan. Therapies that improve overall survival in patients with anthracycline- and taxane-resistant metastatic breast cancer are needed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Melody A. Cobleigh,